Radiation therapy for intracranial tumors in cats with neurologic signs by Körner, Maximilian
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Radiation therapy for intracranial tumors in cats with neurologic signs
Körner, Maximilian
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-161495
Dissertation
Published Version
Originally published at:
Körner, Maximilian. Radiation therapy for intracranial tumors in cats with neurologic signs. 2018,
University of Zurich, Vetsuisse Faculty.
Departement für Kleintiere, Abteilung für Radio-Onkologie                                                            
der Vetsuisse-Fakultät Universität Zürich 
Leiterin: Prof. Dr. med. vet. Carla Rohrer Bley 
 
Arbeit unter wissenschaftlicher Betreuung 
von  Prof. Dr. med. vet. Carla Rohrer Bley 
 
 
Radiation Therapy for Intracranial Tumors 
in Cats with Neurologic Signs 
 
Inaugural-Dissertation 
 
zur Erlangung der Doktorwürde der 
Vetsuisse-Fakultät Universität Zürich 
 
vorgelegt von 
 
Maximilian Körner 
Tierarzt 
aus Wiesbaden, Deutschland 
 
 
genehmigt auf Antrag von 
Prof. Dr. med. vet. Carla Rohrer Bley, Referentin  
 
2018 
	 3	
Inhaltsverzeichnis 
 
Abstract / Zusammenfassung 
Englisch (Originalsprache der Veröffentlichung) 
Deutsch 
 
Seite 4 
Seite 5 
Original Manuskript 
Abstract 
Introduction 
Material and methods 
Results 
Discussion 
References 
 
Seite 6 
Seite 7 
Seite 7 
Seite 8 
Seite 11 
Seite 12 
Danksagung  
Lebenslauf / CV  
 
	 4	
Vetsuisse Faculty, University of Zurich (2018) 
Med. vet. Maximilian Körner 
Departement for Small Animals, Division of Radiation Oncology 
Office: ehuber@vetclinics.uzh.ch  
 Radiation Therapy for Intracranial Tumors in Cats with Neurologic Signs 
Abstract 
The objective of this retrospective multicenter study was to evaluate the outcome of 22 cats with 
intracranial tumors presenting with neurologic signs and/or epileptic seizures treated with 
radiation therapy. 
 
In the treated cats we investigated patient-, tumor- and treatment-related variables for influence 
on local tumor control and survival. Based on advanced imaging characteristics, the treated cats 
presented with meningioma (n=11), pituitary tumor (n=8), choroid plexus tumor (n=2), or glioma 
(n=1). Allocated to the neuraxis, 11 lesions were extra-axial, 3 intra-axial and 8 were located in 
the pituitary region. At diagnosis, 21 cats exhibited altered neurological status. One cat presented 
with epileptic seizures and another cat had both seizures and altered neurological status. The 
mean total physical dose of radiation was 41.63 Gy (± 4.33), range 24-45 Gy. In all but one cat 
(95.5%), neurological signs improved after radiation therapy. The median progression free 
survival was 510 days (95% CI: 51-969). The median overall survival time was 515 days (95% 
CI: 66-964). None of the tested variables influenced outcome. 
 
Radiation therapy seems to represent a viable treatment option in cats with intracranial tumors, 
relieving neurological signs and improving local tumor control. Radiation therapy may be 
considered for cats with tumors in complicated/inoperable localizations or for cases with a high 
peri- and postoperative risk. 
 
Keywords: brain tumor, meningioma, glioma, radiation therapy, pituitary 
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Radiation Therapy for Intracranial Tumors in Cats with Neurologic Signs 
Zusammenfassung 
In dieser retrospektiven multizentrischen Studie wurden die Folgen einer Strahlentherapie bei 22 
Katzen mit einem intrakraniellen Tumor und mit neurologischen Symptomen und/oder 
epileptischen Anfällen evaluiert. 
Es wurden die patienten-, tumor- und behandlungsrelevanten Variablen auf ihren Einfluss auf die 
lokale Tumorkontrolle und das Überleben untersucht. Beruhend auf der Befundung der 
Bildgebung wurden die Katzen mit Meningiomen (n=11), Hypophysen Tumoren (n=8), Choroid 
Plexus Tumoren (n=2) oder Gliomen (n=1) diagnostiziert. Bei der Diagnose zeigten 21 Katzen 
einen veränderten neurologischen Zustand. Eine Katze wurde mit epileptischen Anfällen und eine 
weitere mit epileptischen Anfällen und verändertem neurologischen Zustand vorgestellt. Der 
Mittelwert der Gesamtdosis war 41.63 Gy (± 4.33), mit einer Breite von 24-45 Gy. Ausser in 
einem Fall (95.5%) verbesserten sich die neurologischen Symptome nach der Therapie. Die 
mittlere progressionsfreie Überlebenszeit lag bei 510 Tagen (95% CI: 51-969). Die mittlere 
Überlebenszeit betrug 515 Tage (95% CI: 66-964). Keine der untersuchten Variablen beeinflusste 
das Ergebnis. 
Strahlentherapie scheint eine nützliche Behandlung für Katzen mit intrakranialen Tumoren zu 
sein, führt zur Linderung der neurologischen Symptomatik und optimiert die Tumorkontrolle. 
Eine Bestrahlung sollte besonders in komplizierten, nicht operablen Bereichen, sowie bei Fällen 
mit einem erhöhten peri- und postoperativen Risiko in Betracht gezogen werden. 
 
Schlüsselwörter: Hirntumor, Meningiom, Gliom, Strahlentherapie, hypophysär 
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Radiation therapy for intracranial 
tumours in cats with neurological 
signs
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Abstract
Objectives The aim of this study was to evaluate the outcome of cats with intracranial tumours presenting with 
neurological signs treated with radiation therapy.
Methods This study comprised a retrospective multi-centre case series. Medical records of a total of 22 cats 
with intracranial space-occupying lesions, presenting with neurological signs and/or epileptic seizures and treated 
with external beam radiation therapy, were reviewed. In the treated cats, patient-, tumour- and treatment-related 
variables were investigated, including age, sex, tumour location, tumour volume, total radiation dose, equivalent 
dose in 2 Gy fractions (EQD2), corticosteroid dose, overall treatment time and institution for influence on local 
tumour control and survival.
Results Based on advanced imaging characteristics, the 22 treated cats presented with meningioma (n = 11), 
pituitary tumour (n = 8), choroid plexus tumour (n = 2) or glioma (n = 1). Allocated to the neuraxis, 11 lesions were 
extra-axial, three intra-axial and eight were located in the pituitary region. At diagnosis, 21 cats exhibited altered 
neurological status. One cat presented with epileptic seizures and another cat had both seizures and altered 
neurological status. The mean total physical dose of radiation was 41.63 Gy (± 4.33), range 24–45 Gy. In all but 
one cat (95.5%), neurological signs improved after radiation therapy. The median progression-free survival was 
510 days (95% confidence interval [CI]: 51–969). The proportion free of progression at 1 year was 55.7% (95% CI: 
33–78). Fourteen cats died (only in five cases was death related to the intracranial tumour) and eight cats were 
still alive or lost to follow-up. The median overall survival time was 515 days (95% CI: 66–964). None of the tested 
variables influenced outcome.
Conclusion and relevance Radiation therapy seems to represent a viable treatment option in cats with intracranial 
tumours, relieving neurological signs and improving local tumour control. Radiation therapy may be considered 
for cats with tumours in complicated/inoperable localisations or for cases with a high peri- and postoperative risk.
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Introduction
Neurological signs in cats with primary intracranial 
tumours are common and include altered conscious-
ness (36.8%), circling (31.6%) and epileptic seizures 
(31.6%).1 Symptomatic therapy such as corticosteroids 
and/or antiepileptic medications provides only short-
term relief. Prognosis in these conservatively managed 
patients is poor, with reported survival of 18 days.1–3 
Complete or partial eradication of the tumour with 
surgery is desired in the management of intracranial 
disease and often results in improvement or resolution 
of neurological signs.
The most frequently occurring brain tumour in cats is 
meningioma.1,4 Feline meningioma is often non-invasive 
(World Health Organization grade 1) and located periph-
erally in the calvarium,1,4 which often makes surgery the 
treatment of choice. Surgical excision results in favoura-
ble long-term outcomes with a median survival of 22.8–
37 months.1,2,5 However, invasive tumours or tumours 
located at non-peripheral locations within the calvarium 
may be difficult to remove or may not be amenable to 
surgery.3 Treatment options for cats with inoperable 
intracranial tumours are not well described. In dogs with 
primary intracranial neoplasia of any type presenting 
with neurological signs, radiation therapy is considered 
to be one of the treatments of choice. After radiation 
therapy, an improvement within 6 months or resolution 
of neurological signs associated with a long-term sur-
vival in the range of 2 years is observed in dogs with 
brain tumours.6–9 In cats, response to ionising radiation 
and subsequent tumour control are not known. The few 
studies that describe response to radiation therapy in 
cats presented with neurological signs caused by an 
intracranial tumour are limited to pituitary tumours but 
indicate that neurological amelioration can occur.10–13
In this retrospective multicentre cases series, we 
describe the progression-free survival (PFS) and overall 
survival (OS) in cats with intracranial tumours presented 
with neurological signs after treatment with  radiotherapy 
(RT). We investigated the influence of patient-, tumour- 
and treatment-related variables on local control and 
survival.
Materials and methods
Patients
The databases of the Division of Radiation Oncology of 
the Vetsuisse Faculty, University of Zurich (Switzerland), 
the Centro Oncologico Veterinario (Italy), the Royal 
(Dick) School of Veterinary Studies, Radiation Oncology 
Department, University of Edinburgh (UK) and the 
University of Wisconsin-Madison Veterinary Medical 
Teaching Hospital (USA) were searched for cats with 
primary, non-lymphoid intracranial space-occupying 
lesions with imaging diagnosis of a tumour, presented 
with neurological signs that had been treated with 
radiation therapy alone between January 2002 and June 
2017. Cats that had undergone surgery (complete exci-
sion or debulking) or received any type of systemic anti-
cancer treatment such as chemotherapy were excluded 
from the study. Contributing veterinary radiation oncol-
ogists were asked to collect information from the medi-
cal record of each case including signalment, neurologic 
signs, diagnostic tests, tumour localisation, and imaging-
based diagnosis, medical management (ie, corticosteroids), 
radiation therapy protocol and survival time.
The space-occupying lesions in the brain were diag-
nosed by a board-certified radiologist either by contrast-
enhanced CT or MRI. Due to the lack of histological 
diagnosis, the lesions were allocated to one of three 
groups according to their imaging characteristics: a) 
extra-axial tumours (consistent with meningioma, 
schwannoma and choroid plexus tumour), b) intra-axial 
tumours (consistent with glioma) and c) pituitary 
tumours (consistent with adenoma and adenocarcinoma 
of the pituitary gland).7,14 A second grouping was made 
according to the location of the tumour relative to 
calvarial anatomy: a) rostral cranial fossa (rostral to the 
optic chiasm), b) middle cranial fossa (between the optic 
chiasm and the dorsum sellae and petrosal crests, pitui-
tary/temporal region) and c) caudal cranial fossa 
(between the dorsum sellae and petrosal crests and the 
foramen magnum, including brainstem and cerebel-
lum).15 Lesions suspicious for lymphoma (based on 
diagnostic imaging criteria) were excluded.14 
The patient’s neurological signs at the time of diagno-
sis were grouped into three categories: a) patients with 
altered neurologic status (changes in mentation and 
behaviour, gait and postural abnormalities, deficits of 
cranial nerves including central blindness and head tilt), 
b) patients with only epileptic seizures and c) patients 
with epileptic seizures and altered neurologic status. 
Other information recorded included medical treatment 
at the time of diagnosis, findings regarding tumour stag-
ing and, if available, cerebrospinal fluid analysis.
Treatment
All cats were treated with external beam megavoltage 
radiation therapy. Radiation was delivered with 6 MV 
linear accelerators (Dynaray LA20 [ABB/Varian], Clinac 
DMX or Clinac iX [Varian Medical Systems], Clinac 2100 
C/D [Varian Medical Systems]). 
Treatment planning was performed by a board-certi-
fied veterinary radiation oncologist in all cases, on 
the basis of three-dimensional (3D)-CT datasets and 
using computerised radiation treatment planning sys-
tems (Cadplan [precursor versions of Eclipse], Eclipse 
External Beam Planning system version 8.6, 10.0 and 11.0; 
Varian Oncology Systems). Treatment planning CT scans 
were performed with each patient in the treatment posi-
tion using a customised immobilisation device according 
Körner et al 3
to each institution’s standard practice.16 The gross tumour 
volume (GTV) was defined as the abnormal contrast-
enhancing tissue on CT or MRI images. The clinical 
tumour volume (CTV) was added at the radiation oncol-
ogist’s discretion and a planning target volume (PTV) 
was added to include a safety margin accounting for sys-
tematic and random uncertainties. Organs at risk (nor-
mal brain tissue and eyes) were contoured in all cats. 
Radiation treatment was planned isocentrically using 
photons and 3D conformal radiation therapy. Beam shap-
ing devices such as lead blocks, multi-leaf collimators 
and wedges were used to improve homogeneity and to 
minimise dose to organs at risk. In general, the dose was 
prescribed according to the International Commission on 
Radiation Units & Measurements.17,18 Irradiation was 
delivered in various fractionated regimes.
Follow-up
Contributing veterinary radiation oncologists gathered 
the post-RT follow-up information from the patients’ 
records. If a follow-up diagnostic imaging study was 
available, tumour response was quantified according to 
the response evaluation criteria in solid tumours 
(RECIST) guidelines for dogs.19 The sum of diameters of 
all target lesions was calculated and reported as the 
baseline sum diameter. Complete remission (CR) was 
defined as the disappearance of all target lesions. Partial 
response (PR) was defined as a reduction of at least 30% 
in the sum of diameters of target lesions from baseline. 
Progressive disease (PD) was defined as an increase in 
the sum of diameters of target lesions by at least 20% 
over baseline, or the appearance of new lesions. Tumours 
that showed neither sufficient shrinkage to qualify for 
PR nor sufficient increase to qualify for PD were consid-
ered to be of stable disease (SD). For cats that were not 
re-evaluated at one of the participating centres, the refer-
ring veterinarians and owners were queried by tele-
phone regarding performance status, neurological signs 
compared with those at the time of diagnosis, disease 
progression and date of death by one of the authors 
(MKO, MPA or SCA).
Statistical analysis
Statistical evaluation was performed under the supervi-
sion of a biostatistician (MR) and computed with a com-
mercial statistical software package (IBM SPSS Statistics, 
Version 24). Data were used as submitted in an Excel table 
by the contributing veterinary radiation oncologists. 
Description of quantitative data characteristics, other than 
PFS and overall survival OS, is given by mean (± SD), 
unless otherwise specified. Description of qualitative 
characteristics is provided in absolute and relative 
frequencies. 
PFS was defined as the interval between the first day 
of radiation therapy to measurable progression of 
disease, worsening of neurological signs compared with 
the neurological status before RT, or death. OS was 
defined as the interval between the first fraction of radia-
tion therapy and death. Cats that were free of progres-
sion of measurable tumour and of progression of 
neurological signs and that were alive at the time of data 
collection were censored for PFS analysis. For OS, all 
deaths were considered events and cats that were still 
alive at the time of data collection or lost to follow-up 
were censored at the last date of contact. 
Kaplan-Meier survival analysis was used and fol-
lowed by Logrank test. The univariate Cox-regression 
analysis was used to determine whether the following 
factors were associated with PFS or OS: age, sex, 
meningioma/non-meningioma, meningioma/ pituitary 
tumour, tumour volume (GTV, GTV/brain ratio), treat-
ment volume (PTV, PTV/brain ratio), tumour location, 
treatment institution, dose of radiation (total dose, 
equivalent dose in 2 gray (Gy) fractions [EQD2]), dose of 
corticosteroids at first RT fraction, overall treatment time 
(counted from the first to the last fraction of RT). The 
EQD2 was used to compare the different radiation proto-
cols. Survival estimates at a certain time point are pre-
sented as a percentage with the corresponding 95% 
confidence intervals (95% CI). Median survival time esti-
mates are complemented with 95% CI. The paired 
Wilcoxon test evaluated the change in corticosteroid 
dose from the first to the last RT fraction. Results of sta-
tistical analyses with P value <0.05 were interpreted as 
statistically significant.
Results
Patient and tumour characteristics
Twenty-two cats met the inclusion criteria for this study. 
Nine of the cats were female (nine were spayed) and 13 
were male (12 were castrated). The presented breeds 
included domestic shorthair (n = 18), Persian (n = 3) 
and Selkirk Rex (n = 1). The mean age was 12.0 years (± 
2.3) and ranged from 6.5–16.4 years. The mean body 
weight was 4.5 kg (± 1.4) and ranged from 2.3–8.3 kg. 
Fifteen animals were treated at the Division of Radiation 
Oncology of the Vetsuisse Faculty, University of Zurich, 
Switzerland, six animals at the Centro Oncologico 
Veterinario, Sasso Marconi, Bologna, Italy, and one ani-
mal was treated at the Royal (Dick) School of Veterinary 
Studies Radiation Oncology Service, University of 
Edinburgh, UK. There were no cats that met the inclu-
sion criteria from the University of Wisconsin-Madison 
Veterinary Medical Teaching Hospital, USA.
Based on imaging characteristics, tumours were 
diagnosed as meningioma (n = 11), pituitary tumour 
(n = 8), choroid plexus tumour (n = 2) or glioma (n = 
1). Eleven tumours were considered extra-axial, three 
intra-axial and eight were located in the pituitary 
region. Tumours were distributed in the cranial fossa 
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(n = 9), middle fossa (n = 8) or caudal fossa (n = 5). 
The pretreatment tumour volumes (GTV, absolute 
tumour size) had a mean of 1.78  cm3 (± 1.67) with a 
range of 0.15–7.70 cm3. Mean GTV/brain ratio (relative 
tumour size, [n = 16]) was 8.32 % (± 8.55) and the 
PTV/brain ratio could be derived for 16 cats with a 
mean of 33.18 % (± 34.00). The majority of cats pre-
sented with altered neurological status and without 
epileptic seizures (n = 20). One cat presented with epi-
leptic seizures only (Table 1, case 22) and one cat with 
both altered neurological status and epileptic seizures 
(Table 1, case 21).
Treatment
Twenty-one patients were treated with various definitive-
intent daily-fractionated protocols (Table 1). One patient 
(Table 1, case 20) was treated with a highly conformal 
definitive-intent hypofractionated radiation protocol (3 X 
8 Gy) delivered every other day and received less than 
40.00 Gy of total dose. Total doses ranged from 24.00–45.00 
Gy, with a mean total dose of 41.63 Gy (± 4.33). Fraction 
sizes ranged from 2.25–8.00 Gy, with a mean of 3.32 Gy (± 
1.29). Twenty-one cats were treated using a daily (Monday-
Friday) treatment schedule. Only case 20 (Table 1) was 
treated on a Monday-Wednesday-Friday schedule. All 
Table 1 Individual patient data regarding tumour type and size, radiation protocols, progression-free survival (PFS) and 
overall survival (OS)
Case Age 
(years)
Sex Tumour  
type‡
GTV 
(cm3)
Number 
of 
fractions
Treatment 
schedule
Dose/
fraction 
(Gy)
Total 
dose 
(Gy)
EQD2 
(Gy2)
PFS 
(days)
OS 
(days)
1 8 mc Meningioma 4.19 10 Daily 4 40 46.7 204* 204*
2 13 mc Meningioma 0.51 10 Daily 4 40 46.7 121* 121*
3 11 fs Meningioma 0.86 14 Daily 3 42 45.5 740 963†
4 11 fs Meningioma 1.60 18 Daily 2.5 45 46.9  50 50
5 14 fs Meningioma 0.15 14 Daily 3 42 45.5  63 63
6 12 mc Meningioma 0.61 19 Daily 2.25 42.75 43.6 225* 225*
7 10 mc Meningioma 3.49 20 Daily 2.25 45 45.9 535 540¶
8 10 mc Meningioma 2.35 20 Daily 2.25 45 45.9 515 520¶
9 11 fs Meningioma 7.70 20 Daily 2.25 45 45.9 510 515¶
10 14 fs Meningioma 1.10 14 Daily 2.9 40.6 43.6  91 91
11 14 mc Meningioma 2.35 20 Daily 2.25 45 45.9 174 174
12 13 mc Pituitary gland 
tumour
2.55 10 Daily 4 40 46.7 839* 839*
13 16 mc Pituitary gland 
tumour
0.72 10 Daily 4.2 42 49.7  55 55
14 13 mc Pituitary gland 
tumour
1.17 14 Daily 3 42 45.5  70 70
15 12 fs Pituitary gland 
tumour
0.82 10 Daily 4.2 42 49.7 644* 644*
16 7 m Pituitary gland 
tumour
1.42 17 Daily 2.5 42.5 44.3  76* 76*
17 12 mc Pituitary gland 
tumour
1.20 14 Daily 3 42 45.5 775 1056†
18 12 mc Pituitary gland 
tumour
2.10 14 Daily 3 42 45.5 144 144¶
19 11 fs Pituitary gland 
tumour
1.44 20 Daily 2.25 45 45.9 99 99
20 12 mc Choroid plexus 
tumour
0.17 3 MWF 8 24 36.0 558* 558*
21 15 fs Choroid plexus 
tumour
1.60 10 Daily 4 40 46.7 265 276¶
22 14 fs Glioma 1.01 10 Daily 4.2 42 49.7 575* 575*
m = male; mc = male castrated; fs = female spayed; GTV = gross tumour volume; EQD2 = equivalent dose delivered in 2 Gy fractions; MWF = 
Monday-Wednesday-Friday
*Cats free of progression and alive at the time of data evaluation or lost to follow-up were censored
†Cats were re-irradiated at the time of progression and censored from analysis of OS at the start of the second course of radiation therapy
‡Tumour type is based on advanced imaging characteristics
¶Died of tumour-or treatment-related causes
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cats completed the full course of the planned radiation 
therapy. The respective EQD2 were 36.00–49.70 Gy2, with 
a mean of 45.79 Gy2 (± 2.74). Mean overall treatment time 
was 19.6 days (5–29 days). 
Pretreatment corticosteroid treatment with predniso-
lone was given to 20/22 cats with a mean dose of 0.66 
mg/kg (± 0.41) q24h PO and tapered to mean doses of 
0.58 mg/kg (± 0.43) q24h PO post-RT (P = 0.076). Three 
cats received antiepileptic treatment consisting of either 
phenobarbital (n = 2) or levetiracetam (n = 1) pre-, dur-
ing and post-RT. Two of these cats had epileptic seizures 
at initial presentation and one received phenobarbital 
prophylactically and was tapered off the medication 
after RT, as no epileptic seizures were observed.
Outcome and prognostic factors
Median follow-up time for censored cases (n = 8, still 
alive or lost to follow-up) was 575 days (95% CI: 464–
686). Fourteen of the 22 cats died during the study 
period. Death was attributed to the brain tumour or pos-
sible treatment-related toxicity in 5/14 cats (35.7%). In 
the 64.3% of animals that died due to other causes, death 
was related to other neoplastic disease (n = 4, histiocytic 
sarcoma in the liver [Table 1, case 4], lymphosarcoma in 
the bladder [Table 1, case 5], oral sarcoma [Table 1, case 
10], intestinal lymphoma [Table 1, case 13]), and tumour-
unrelated medical problems (not accompanied with neu-
rological symptoms) such as hyperthyroidism (Table  1, 
case 11), cardiac failure with dilated atria, arrhythmia and 
mild pericardial effusion (Table 1, case 14) or pyothorax 
(Table 1, case 19). In two cases (Table 1, cases 3 and 17) 
the cats died at home with general weakness. Tumour 
recurrence could not be ruled out because no necropsy 
was performed, so the real cause for death remains 
unknown in these two cases.
Based on medical records and owner communication, 
clinical and neurological status improved in 21/22 (95.5%) 
cats, compared with the pre-treatment complaints. One of 
the 22 cats was judged to have stable clinical signs (Table 1, 
case 18). In the patient in which epileptic seizures was the 
only presenting complaint, it was difficult to determine 
whether seizure control was attributable to reduction of 
tumour/oedema or to anti-epileptic medication.
A total of 10 post-RT diagnostic imaging examinations 
were performed in six patients. CT was performed four 
times (n = 3 cats), and MRI was performed six times (n = 
3 cats). On MRI, one cat with a meningioma showed par-
tial remission at 6 months post-RT (Table 1, case 1), a sec-
ond cat with a meningioma showed stable disease at 3, 6 
and 12 months post-RT (Table 1, case 6). Another cat with 
a pituitary gland tumour showed stable disease on MRI at 
6 and 12 months post-RT (Table 1, case 12). In the CT of 
one cat 6 months post-RT, the tumour was in partial remis-
sion (the 12 month re-check CT of the same cat was made 
at another clinic and tumour volume was not measured) 
(Table 1, case 15). Tumours of two cats were measured 24 
months post-RT; one cat still showed stable disease (Table 
1, case 17) and the other cat was scanned upon re-occur-
rence of neurological signs and was found to have a dis-
ease progression on CT (Table 1, case 3). Overall, seven 
cats (31.8%) were considered to have a disease progres-
sion either of increased volume based on imaging (n = 1) 
or of progression of neurological signs (n = 6).
The median PFS time for all 22 cases was 510 days 
(95% CI: 51–969). The proportion free of progression at 1 
year was 55.7% (95% CI: 33–78) (Figure 1). Of the nine 
cats that died within the first year after RT, seven (77.8%) 
died of causes unrelated to the brain tumour (Table 1, 
cases 4, 5, 10, 11, 13, 14 and 19) and two (22.2%) died 
because of the brain tumour or treatment-related toxicity 
(Table 1, cases 18 and 21). No difference was seen in PFS 
between the patients treated at the different institutions 
(P = 0.634). At the time of tumour progression, two cats 
were re-irradiated, resulting in an additional progres-
sion-free interval of 223 and 281 days (Table 1, cases 3 and 
17). Both cases were censored from analysis of OS at the 
start of the second course of radiation therapy. Neither 
the patient-related (age, sex), tumour-related (meningi-
oma/non-meningioma, meningioma/pituitary tumour, 
tumour size, tumour location) nor treatment-related 
parameters (dose of radiation [total radiation dose or 
EQD2], corticosteroid dose at first RT, overall treatment 
time, treatment institution) were associated with PFS.
Figure 1 Median progression-free survival (PFS). The 
dotted line marks 1 year. Tick marks: cats that were free of 
progression of measurable tumour and of progression of 
neurological signs and that were alive at the time of data 
collection were censored for PFS analysis. Of the nine cats 
that died within the first year after radiotherapy, seven (77.8%) 
died of causes unrelated to the brain tumour and two (22.2%) 
died because of the brain tumour or treatment-related toxicity
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Median OS was 515 days (95% CI: 66–964). The pro-
portion alive at 1 year was 56 % (95% CI: 33–79) and at 2 
years 37% (95% CI: 15–60) (Figure 2). No difference was 
seen in OS between the patients treated at the different 
institutions (P = 0.695). None of the tested variables had 
a statistically detectable influence on OS.
Discussion
Intracranial tumours causing neurological signs in cats are 
often of extra-axial and non-infiltrative nature and can be 
successfully treated with surgery.1–5 Meningiomas with 
and without neurological signs are the most common 
intracranial tumours in cats and postoperative median sur-
vival times were found to range between 22.8 to 37 
months.1,2,5 For feline patients with tumours in less acces-
sible locations, such as tentorially located meningiomas, 
survival time was found to decrease to 19 months postop-
eratively.3 The risk of fatal intra- or postoperative complica-
tions ranged between 6–19%2,3,5 and, depending on primary 
tumour location, the postoperative recurrence rate was 12–
21%1,2,5 and 100% for tentorial meningiomas3. In these ret-
rospective studies, a selection bias of only including 
surgically amenable tumours should be considered.
For cats with inoperable tumours, however, literature 
findings are scarce and limited to cases of pituitary neo-
plasia and a case report of a cat with oligodendroglioma 
treated with radiation therapy.10–13,20 Surprisingly, ame-
lioration of neurologic symptoms was rapid and often 
complete in most cats and survival times increased from 
a median of 1.1–1.7 months if treated with corticoster-
oids only1 to a range of 5.5–20.5 months after radia-
tion.10–13 These results are difficult to compare to our 
findings, as in the cats treated for pituitary tumours only, 
38.9% had neurologic symptoms and most of them were 
treated because of pituitary-dependent endocrine dis-
ease. However, as is known from dogs with pituitary 
tumours treated with radiation therapy, radiation ther-
apy also prolonged survival in non-neurologic patients 
by delaying the onset of neurologic signs.21 In dogs with 
an intracranial primary tumour and neurologic signs, 
fractionated radiation therapy is often considered the 
treatment of choice with durable tumour control in the 
range of 19.2–25.2 months.6–9
In this study, the outcomes of cats with intracranial 
tumours presented with neurological signs were retro-
spectively compiled. Cases were sought from four insti-
tutions, and only three institutions could contribute 
patients. This fact indicates the scarcity of brain tumours 
in cats. After radiation therapy, the neurological status 
improved in all but one cat (95.5%). Median OS was 17.2 
months, with 56% of cats alive at 1 year after therapy. 
Surprisingly, only seven patients (32%) were considered 
to have disease progression during the time of follow-
up. Most patients (9/14) died of other neoplastic dis-
eases or unrelated medical problems. Upon recurrence 
of disease, two cats in this cohort were re-irradiated and 
attained an additional progression-free interval of 7.4 
and 9.2 months (Table 1, cases 3 and 17, respectively). 
None of the investigated factors such as age, sex, treat-
ment institution, tumour location (extra-axial, intra-
axial, pituitary), tumour type, tumour size, regions of 
brain affected, total dose, EQD2, corticosteroid dose at 
first RT or overall treatment time were found to correlate 
with PFS or OS.
We acknowledge the following limitations of this 
study that should direct future research approaches. a) 
The cats were treated at different institutions, with vari-
ous non-standardised radiation protocols in terms of 
fraction size, total dose, overall treatment times, target 
volumes and treatment planning practices, equipment 
and patient position verification. In order to not skew 
the data into a direction, we decided to keep patients 
treated with all fraction schedules in the investigated 
group. b) Standardised neurological evaluation, severity 
of neurological signs and routine follow-up diagnostic 
imaging were not available, which should constitute an 
important focus for further evaluation of tumour 
response to radiation therapy. c) Improvement of the 
clinical signs could – at least in part – also be attributed 
to medical supportive treatment such as corticosteroids. 
d) The patient population consisted of a heterogeneous 
group, with varying unconfirmed tumour types. 
Presumptive tumour diagnoses were made according to 
advanced diagnostic imaging techniques.14 Most of the 
Figure 2 Median overall survival (OS): the dotted line marks 
1 year. Tick marks: cats that were still alive at the time of data 
collection or lost to follow-up were censored at the last date 
of contact
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tumours were meningiomas (50%) or pituitary adeno-
mas (36%), which are commonly non-infiltrative and 
hence less aggressive. Furthermore, due to the limited 
number of patients, statistical analysis for each tumour 
type was not performed. e) The patients were referred 
for radiation therapy and the possibility of resectability 
was not uniformly judged. f) Due to the retrospective 
nature of the study and the lack of follow-up imaging it 
was not in every case possible to differentiate tumour 
progression from radiation toxicity as the cause of recur-
ring neurological signs.
Conclusion
Findings of this study suggest radiation therapy as a 
viable treatment option for cats with intracranial 
tumours presented with neurological signs. Case selec-
tion should focus on inoperable disease or patients with 
an estimated high peri- and postoperative risk.
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